Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Marksans-Pharma-Limited"

9 News Found

Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules
Drug Approval | October 05, 2023

Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules

This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals


Marksans Pharma announces USFDA approval for Famotidine Tablets
News | March 11, 2023

Marksans Pharma announces USFDA approval for Famotidine Tablets

Marksans' OTC Famotidine Tablets USP are acid reducers


Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
News | January 24, 2023

Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK


Marksans to acquire Tevapharm's bulk formulations business
News | October 12, 2022

Marksans to acquire Tevapharm's bulk formulations business

Plans to double its manufacturing footprint to bolster the growth


Marksans Pharma posts Q1FY23consolidated PAT at Rs. 59.71 Cr
News | August 16, 2022

Marksans Pharma posts Q1FY23consolidated PAT at Rs. 59.71 Cr

The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.


Briefs: Marksans Pharma and Alkem
News | June 22, 2022

Briefs: Marksans Pharma and Alkem

The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.


Marksans announces US FDA approval for Acetaminophen Extended- Release tablets
News | August 27, 2021

Marksans announces US FDA approval for Acetaminophen Extended- Release tablets

The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India


Marksans Pharma shareholders vote for warrants worth Rs. 365 Cr
News | July 11, 2021

Marksans Pharma shareholders vote for warrants worth Rs. 365 Cr

The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant


Marksans Pharma Q4 FY21 profit up 86%
News | June 01, 2021

Marksans Pharma Q4 FY21 profit up 86%

The company's operating revenue for Q4 FY21 was Rs. 330.2 crore